Novavax, Inc.
NVAX
$9.06
-$0.29-3.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 139.51M | 147.14M | 70.45M | 239.24M | 666.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 139.51M | 147.14M | 70.45M | 239.24M | 666.66M |
| Cost of Revenue | 112.43M | 135.96M | 103.70M | 80.29M | 89.91M |
| Gross Profit | 27.09M | 11.18M | -33.26M | 158.95M | 576.75M |
| SG&A Expenses | 37.12M | -9.76M | 46.12M | 53.28M | 60.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 149.54M | 126.20M | 149.83M | 133.57M | 150.64M |
| Operating Income | -10.03M | 20.94M | -79.38M | 105.67M | 516.01M |
| Income Before Tax | -8.51M | 17.90M | -203.04M | 107.45M | 519.85M |
| Income Tax Expenses | 985.00K | 376.00K | -657.00K | 946.00K | 1.20M |
| Earnings from Continuing Operations | -9.49M | 17.53M | -202.38M | 106.51M | 518.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.49M | 17.53M | -202.38M | 106.51M | 518.65M |
| EBIT | -10.03M | 20.94M | -79.38M | 105.67M | 516.01M |
| EBITDA | -6.97M | 26.06M | -72.80M | 113.23M | 524.35M |
| EPS Basic | -0.06 | 0.11 | -1.25 | 0.66 | 3.22 |
| Normalized Basic EPS | -0.01 | 0.11 | -0.29 | 0.43 | 2.02 |
| EPS Diluted | -0.06 | 0.11 | -1.25 | 0.62 | 2.93 |
| Normalized Diluted EPS | -0.01 | 0.11 | -0.29 | 0.40 | 1.83 |
| Average Basic Shares Outstanding | 163.28M | 162.53M | 162.35M | 162.02M | 161.05M |
| Average Diluted Shares Outstanding | 163.28M | 165.18M | 162.35M | 177.22M | 177.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |